MCL1 and neoplasm: This effect was confirmed using dynamic BH3 profiling and extended to clinical samples using an elegant approach combining flow cytometry-based BH3 profiling with tumor-specific antibodies to ensure that therapy-induced MCL-1 priming effects were observed in tumor cells and not just the contaminating stroma.